Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,387

Document Document Title
WO/2022/168755A1
The present invention provides a nonaqueous electrolyte solution comprising: (I) at least one compound selected from the group consisting of compounds represented by general formula (1) in the description (for example, compounds represen...  
WO/2022/166767A1
Disclosed are a pharmaceutically acceptable salt of an HA inhibitor (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridine-4-yl) benzo[d]oxazol-5-yl) cyclopropyl-1-carboxamide, or a h...  
WO/2022/163843A1
Provided are a compound having high PIM2 inhibitory activity, and a PIM2 inhibitor and a pharmaceutical composition that contain the compound. This PIM2 inhibitor contains a compound represented by formula (1) (in the formula, A is a ben...  
WO/2022/165198A1
A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut...  
WO/2022/158758A1
Provided is an organic compound which contributes to substantial improvements in the luminous efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention c...  
WO/2022/156737A1
Disclosed are a crystal form of a compound (1S, 2S)-2-fluoro-N-(2-(2-(4-((R)-(5-methyl-2H-tetrazol-2-yl) (phenyl) methyl) piperidine-1-formyl) pyridin-4-yl) benzo [d] oxazol-5-yl) cyclopropyl-1-carboxamide having a structure of formula (...  
WO/2022/159445A1
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...  
WO/2022/146086A1
The present invention relates to: a compound that is sensitive to γ-hydroxybutyric acid (GHB)-based compounds, and thus changes color; and an application thereof, and since the GHB-based compound-sensitive chromogenic compound of the pr...  
WO/2022/136366A1
The present invention relates to a novel method for producing NCA compounds. The invention also relates to a novel use of a peptide coupling agent. The method according to the invention enables NCA compounds to be obtained from α-amino ...  
WO/2022/140520A1
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...  
WO/2022/138944A1
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...  
WO/2022/132696A1
The present invention is directed to urea compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psy...  
WO/2022/127704A1
Disclosed are a method for preparing a carboxyl cyclic acid anhydride and a prepared product thereof. A method for preparing a compound of formula (II), comprising the steps of reacting a compound of formula (I) with a cyclization reagen...  
WO/2022/129047A2
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...  
WO/2022/129909A1
The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psyc...  
WO/2022/122773A1
The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl) carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as R...  
WO/2022/121228A1
Disclosed are a preparation and an application of an oxazole and thiazole histone deacetylase (HDAC) inhibitor. The chemical structure of the inhibitor is represented by formula (I). The inhibitor has relatively strong inhibitory activit...  
WO/2022/112140A1
The present invention provides novel compounds having the general formula (I) wherein Al to A4, Li, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds for the treatment of HBV i...  
WO/2022/111605A1
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...  
WO/2022/109362A1
This disclosure relates to aryl amidines of Formula (I) and their use as fungicides.  
WO/2022/107166A1
The present invention relates to novel crystalline Forms of Tafamidis and process to prepare thereof. The present invention also relates to process of Tafamidis N-methyl-D-glucamine.  
WO/2022/106589A1
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2022/100099A1
An organic compound, a mixture, a composition and an organic electroluminescence device. The organic compound has a high extinction coefficient in the ultraviolet region; has a high refractive index in the visible light region; can be us...  
WO/2022/095569A1
Disclosed are a heterocyclic compound for an immune checkpoint inhibitor capable of blocking a VISTA signaling pathway, and a preparation method therefor and a use thereof. The compound is as represented by formula I. The compound has a ...  
WO/2022/092260A1
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...  
WO/2022/087719A1
Provided are methods of treating SpA, uses for treating SpA and compositions for treating SpA. The methods involve administering a MIF inhibitor to a subject in need thereof. The MIF inhibitor can be a compound or an anti-MIF antibody.  
WO/2022/084790A1
The present invention relates to process for preparation of crystalline Form 4 of tafamidis. The present invention also relates to salts of tafamidis and process of preparation of salts of tafamidis. The present invention also relates to...  
WO/2022/083728A1
Disclosed are an intermediate of pregabalin and a preparation method therefor. Provided are a compound as represented by formula (I) and a preparation method therefor. The preparation method for the compound as represented by formula (I)...  
WO/2022/080696A1
Provided is a high-refractive-index benzazole derivative that effectively absorbs a high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contribute...  
WO/2022/078294A1
The present disclosure provides substituted heteroaryl compounds and use thereof, also provides compounds or pharmaceutically acceptable salts or solvates thereof as PAD inhibitors and their use in treatment of a disease or disorder.  
WO/2022/077196A1
Disclosed is an environmentally friendly preparation method for a substituted oxazole compound, said method uses an N-substituted formyl-α-substituted glycinate as a starting material, and a substituted oxazole compound is obtained unde...  
WO/2022/076628A1
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the structure: (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis usin...  
WO/2022/074068A1
The present invention describes disorazoles and their analogues as described in formula III wherein the variables are defined in the description, or pharmaceutically acceptable salts thereof. Described is also a novel synthetic pathway f...  
WO/2022/072820A1
The present disclosure provides lyophilates comprising (S)-isopropyl 2-((S)-2- acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoa te: for subcutaneous administration to a subject, and pharmaceutical compositions, pharmaceutical...  
WO/2022/062288A1
Disclosed are an aniline anhydride, a preparation method therefor, and a polyaminoacid graft chain. In the presence of an acid binding agent, an addition-elimination reaction is carried out between N-phenyl amino acid and Boc anhydride t...  
WO/2022/058733A1
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...  
WO/2022/053660A2
The use of an N-heterocyclic compound of the general formula (a) or (b) with the following definitions: X1 being S or O, X2 being S or O and at least one of X1 and X2 being S R2 H or C1-4-alkyl, R3 H or C1-4-alkyl R6 and R7 are hydrogen ...  
WO/2022/053318A1
The present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic reagents and reduce salts by-products with high efficiency, wherein R1 is H, or lower alkyl or aryl optionally substitut...  
WO/2022/053317A1
The present invention provides a process for producing oxazole compounds by direct cyclodehydration of acyloxy enamines in the presence of anhydride. According to the present invention, the oxazole compounds can be produced in a higher y...  
WO/2022/049376A1
The invention relates to compounds of formula (I): and related aspects.  
WO/2022/047014A1
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...  
WO/2022/045618A1
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...  
WO/2022/038224A1
A method for the preparation of an alpha-substituted carbonyl compound or an alpha- substituted nitrile compound carrying an aryl or heteroaryl group as an alpha-substituent, said method comprising reacting a sulfoxide compound S1 compri...  
WO/2022/038356A1
The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparatio...  
WO/2022/040324A1
The present disclosure is generally directed to modulators of hydroxysteroid dehydrogenase enzymes useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), Formula (II), or Formula (III).  
WO/2022/029357A1
The present invention relates to a compound 1 or 2 or a composition comprising same. The present invention also relates to a method for producing a compound 1 or 2, and the use thereof to detect GHB in drinks and urine. The invention als...  
WO/2022/028941A1
The present invention provides a new process for producing an oxazole compound of formula (I), which can avoid toxic and corrosive reagent, and salts by-products and has high efficiency,formula (I). Wherein R is H, or lower alkyl or aryl...  
WO/2022/026500A1
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...  
WO/2022/009221A1
The present disclosure relates to novel solid forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of Formula (I) and it pharmaceutically acceptable salts thereof.  
WO/2021/261851A1
The present invention provides an organic electric element and an electronic device comprising the organic electric element, the organic electric element comprising an anode, a cathode, and an organic layer and a capping layer formed bet...  

Matches 1 - 50 out of 9,387